During the past decade, Institute of Metabolic Diseases conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Institute of Metabolic Diseases" are "Dyslipidemia" (2 trials), "Hypercholesterolemia" (2 trials), "Acromegaly" (1 trials), "Dyslipidemias" (1 trials) and "Endogenous Cushing's Syndrome" (1 trials). Many other conditions were trialed in "Institute of Metabolic Diseases" in a lesser frequency.

Most popular intervention types in "Institute of Metabolic Diseases" are "Drug" (7 trials). Other intervention types were less common.

The name of intervention was led by "Pitavastatin" (4 trials), "Placebo" (2 trials), "Actos" (1 trials), "Atorvastatin" (1 trials) and "Debio 4126" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Metabolic Diseases" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Institute of Metabolic Diseases". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Institute of Metabolic Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Metabolic Diseases, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".